Resolve past grudges! Hims & Hers (HIM.US) reaches weight loss drug authorization agreement with Novo Nordisk A/S Sponsored ADR Class B (NVO.US), causing stock price to skyrocket 55% before market opening.

According to informed sources, Novo Nordisk A/S Sponsored ADR Class B (NVO.US) is set to reconcile with Hims & Hers Health Inc. (HIM.US) and plans to announce a new collaboration agreement as early as Monday. The Danish pharmaceutical company will authorize the sale of its weight loss drugs on the Hims platform, thus ending the public dispute between the two parties. Boosted by this news, Hims' stock price surged 55% in pre-market trading, while Novo Nordisk A/S Sponsored ADR Class B rose by about 1%. It is understood that the two parties reached a similar agreement last year, but Novo Nordisk A/S Sponsored ADR Class B unilaterally terminated the cooperation because Hims refused to stop marketing generic drugs. This collaboration has surprised the market - just in February this year, Novo Nordisk A/S Sponsored ADR Class B filed a lawsuit against Hims for allegedly launching a generic version of Wegovy, a new weight loss drug, which is a core product in the pharmaceutical giant's growth strategy. The Danish pharmaceutical company pointed out that Hims' actions violated the US patents of the key ingredients of its flagship drugs Ozempic and Wegovy. At the time, John Kuckelman, Chief Legal Counsel for Novo Nordisk A/S Sponsored ADR Class B, criticized Hims' statement as "extremely malicious." In response to the latest developments, a spokesperson for Novo Nordisk A/S Sponsored ADR Class B stated last week: "We have always maintained dialogue with companies dedicated to improving access to FDA-approved drugs for chronic disease patients, and such discussions are ongoing work."